Molecular imaging · 2024
Quantification of Multi-Organ 11β-Hydroxysteroid Dehydrogenase Type 1 Enzyme Levels in a Zucker Fatty Rat Model: A PET Imaging Study.
СтатьяПоддержка NIH: внешняя программаНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Bini Jason, Strober Jordan, Kapinos Michael, Zheng Ming-Qiang, Li Songye, Ropchan Jim, Nabulsi Nabeel, Huang Yiyun, Perry Rachel J, Vatner Daniel F, Carson Richard E
Аннотация
BACKGROUND: In rodents, 11β-hydroxysteroid dehydrogenase 1 (11β-HSD1) catalyzes the conversion of inactive 11-dehydrocorticosterone to the active hormone corticosterone. Dysregulation of intracellular glucocorticoid action is implicated in metabolic diseases. Assessing 11β-HSD1 enzyme levels in vivo may be key to understanding obesity pathophysiology.
OBJECTIVE: We used a Zucker Fatty (ZF) rat model and [18F]AS2471907 PET imaging to determine appropriate kinetic modeling methods and assess changes in 11β-HSD1 levels due to obesity in the liver, white and brown adipose tissue (WAT/BAT), and brain.
MATERIAL AND METHODS: To validate [18F]AS2471907 PET in preclinical models, time-activity curves (TACs) were generated and kinetic modeling was performed with image-derived input functions (IDIFs) extracted from multiple locations. Quantitative estimates of radioligand binding were compared with ex vivo 11β-HSD1 protein expression. Validated quantitative PET kinetic modeling methods were then used to assess differences in 11β-HSD1 between lean and obese ZF rats. Metabolic disease status was confirmed with stable isotopes tracer studies of glucose and fatty acid metabolism.
RESULTS: Obesity is associated with decreased brain 11β-HSD1 levels, measured by [18F]AS2471907 PET, which correlated with measures of glucose and fatty acid metabolism.
CONCLUSION: We demonstrate that [18F]AS2471907 PET can provide useful quantification of 11β-HSD1 levels in a rodent model of obesity.
OBJECTIVE: We used a Zucker Fatty (ZF) rat model and [18F]AS2471907 PET imaging to determine appropriate kinetic modeling methods and assess changes in 11β-HSD1 levels due to obesity in the liver, white and brown adipose tissue (WAT/BAT), and brain.
MATERIAL AND METHODS: To validate [18F]AS2471907 PET in preclinical models, time-activity curves (TACs) were generated and kinetic modeling was performed with image-derived input functions (IDIFs) extracted from multiple locations. Quantitative estimates of radioligand binding were compared with ex vivo 11β-HSD1 protein expression. Validated quantitative PET kinetic modeling methods were then used to assess differences in 11β-HSD1 between lean and obese ZF rats. Metabolic disease status was confirmed with stable isotopes tracer studies of glucose and fatty acid metabolism.
RESULTS: Obesity is associated with decreased brain 11β-HSD1 levels, measured by [18F]AS2471907 PET, which correlated with measures of glucose and fatty acid metabolism.
CONCLUSION: We demonstrate that [18F]AS2471907 PET can provide useful quantification of 11β-HSD1 levels in a rodent model of obesity.